Αποτελέσματα Αναζήτησης
Raloxifene (Evista®): An estrogen agonist/antagonist (or selective estrogen receptor modulator) approved by the FDA for prevention and treatment of osteoporosis. It lowers the risk of vertebral fracture by about 30% in patients with and about 55% in patients without prior vertebral fracture.
The goal of osteoporosis management is to prevent fractures. Several pharmacological agents are available to lower fracture risk, either by reducing bone resorption or by stimulating bone formation.
18 Ιουλ 2023 · For patients with osteoporosis, the long-term use of bone-specific pharmacological therapies, including antiresorptive and/or osteoanabolic approaches, has raised concerns around adverse effects...
This article will review the pathophysiology, etiology, screening, and diagnosis of osteoporosis; selected professional guidelines and recommendations; nonpharmacological management; pharmacological options; and the cost-effectiveness of those options.
16 Σεπ 2023 · Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis.
26 Αυγ 2024 · Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone formation. Bisphosphonates inhibit bone resorption with relatively few side effects. As a result, they are widely used to prevent osteoporotic fractures.
1 Μαΐ 2023 · Biomaterials-based therapeutic strategies have recently emerged as promising alternatives for the treatment of osteoporosis. The present review summarizes the current status of biomaterials designed for managing osteoporosis. The advantages of biomaterials-based strategies over conventional systematic drug treatment are presented.
